A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the first line treatment of postmenopausal women with hormone positive metastatic or locally advanced breast cancer

Trial Profile

A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the first line treatment of postmenopausal women with hormone positive metastatic or locally advanced breast cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Everolimus (Primary) ; Letrozole (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 11 Aug 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 03 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top